title: Alpha-adrenergic receptors mediate the hypertriglyceridemia induced by endotoxin, but not tumor necrosis factor, in rats.
abstract: We assessed the role of catecholamines in mediating the hypertriglyceridemia induced by lipopolysaccharide (LPS) or tumor necrosis factor-alpha (TNF alpha) in rats by employing specific adrenoreceptor antagonists. Pretreatment with phentolamine, an alpha-antagonist, but not propranolol, a beta-antagonist, suppressed the hypertriglyceridemia induced by either low dose LPS (100 ng/100 g BW) or high dose LPS (50 micrograms/100 g BW). Prazosin, an alpha 1-selective antagonist, significantly suppressed the low dose LPS-induced hypertriglyceridemia by inhibiting hepatic triglyceride secretion, but did not affect the increase in lipolysis. In contrast, yohimbine, an alpha 2-selective antagonist, partially suppressed the high dose LPS-induced hypertriglyceridemia by inhibiting the decrease in postheparin lipoprotein lipase activity. Treatment with phentolamine and propranolol did not affect the hypertriglyceridemia induced by TNF alpha. In summary, these findings suggest that catecholamines via alpha-adrenergic, but not beta-adrenergic, receptors are mediators of the hypertriglyceridemia induced by either low or high dose LPS in rats. alpha 1-Adrenergic receptors are involved in mediating the increased hepatic triglyceride secretion induced by low dose LPS, whereas alpha 2-adrenergic receptors are involved in mediating the decrease in lipoprotein lipase activity induced by high dose LPS. The hypertriglyceridemia induced by either low or high dose LPS may be regulated by a mechanism unrelated to TNF alpha in rats.
authors.affiliation: Department of Medicine, University of California, San Francisco 94143.
authors.forename: K
authors.initials: K
authors.lastname: Nonogaki
authors.forename: A H
authors.initials: AH
authors.lastname: Moser
authors.forename: K R
authors.initials: KR
authors.lastname: Feingold
authors.forename: C
authors.initials: C
authors.lastname: Grunfeld
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D002395:Catecholamines / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004731:Endotoxins; D015228:Hypertriglyceridemia / Q000097:blood / Q000139:chemically induced*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008071:Lipoprotein Lipase / Q000097:blood; D008074:Lipoproteins / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D011942:Receptors, Adrenergic, alpha / Q000502:physiology*; D014280:Triglycerides / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000317:Adrenergic alpha-Antagonists; D002395:Catecholamines; D004731:Endotoxins; D008070:Lipopolysaccharides; D008074:Lipoproteins; D011942:Receptors, Adrenergic, alpha; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D008071:Lipoprotein Lipase